Phase 3 Readout~month
Phase 3 Topline: A Phase 3, Multi-center, Randomized, Quadruple-blind, Placebo-controlled Study to Assess the Efficac
- Company
- Immunovant, Inc. (IMVT)
- Drug
- generalized
- Indication
- Generalized Myasthenia Gravis
Other upcoming events for IMVT
Track this catalyst and more
Get real-time alerts, AI-powered analysis, and full catalyst coverage.